Industry Trend Analysis - Poor Pharmaceutical Policy Enforcement To Limit Drugmaker Opportunities - APR 2017


BMI View: Attempts to increase the accessibility and affordability of medicines in Moldova have had minimal impact through 2016. This will result in maintained weak demand for medicines, limiting growth within the dominant generic medicine sector. Innovative pharmaceutical firms will continue to view Moldova as a high - risk low - reward market due to the combination of small market size , and high political and economic risks.

Moldova will remain the least attractive pharmaceutical market for innovative drugmakers in the Central and Eastern Europe region, and on a global level the market also poses a high level of risk with little opportunity for reward. The risks posed to drugmakers is exemplified by recent controversy over proposed medicine reductions while political tensions, weak demographics and a small market expenditure will also pose headwinds to revenue growth.

BMI's Innovative Pharmaceuticals Risk/Reward Index is a tool that quantifies and ranks a market's attractiveness for innovative drugmakers by balancing the risks and rewards of launching a product in that market. Rewards are divided into country- and industry-specific factors including medicine expenditure, sector value growth and demographics. Risks are also divided into country- and industry-specific factors such as pricing regime, protectionism and BMI's Political Risk indices. Moldova scores below both the CEE and global average for both industry risks and rewards.

An Unattractive Market
Innovative Pharmaceuticals Risk/Reward Index
Note: Scores out of 100; higher scores = lower risk/higher reward. Source: BMI

This article is part of our Emerging Europe coverage. To access this article subscribe now or sign up for free trial